Prescription drug · ANDA
Pomalidomide NDC 60505-4499
Pomalidomide 3 mg/1 · Capsule · Oral · Apotex Corp.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 60505-4499-2 | 60505449902 | 21 CAPSULE in 1 BOTTLE (60505-4499-2)Marketed from Mar 11, 2026 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Pomalidomide
- Generic name (nonproprietary)
- pomalidomide
- Active ingredients
- Pomalidomide — 3 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Apotex Corp.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 210164
- Marketing start
- Listing expires
- Identifiers
- Product ID 60505-4499_79028ff4-3130-88ed-e3fc-18a7d9a779b8SPL ID 79028ff4-3130-88ed-e3fc-18a7d9a779b8SPL set ID b1a1c713-d23b-5ede-1ae0-0bbba47221dfRxCUI 1369718, 1369726, 1369730, 1369734UNII D2UX06XLB5
- Pharmacologic class
- Thalidomide Analog
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N460505449902followed by a unit qualifier and the quantityPackage 60505-4499-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Pomalidomide capsules are a thalidomide analogue indicated, for the treatment of adult patients: in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV- negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description o…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 210164
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Pomalidomide | Pomalidomide 1 mg/1 | CapsuleOral | Apotex Corp. | 60505-4497 |
| Pomalidomide | Pomalidomide 2 mg/1 | CapsuleOral | Apotex Corp. | 60505-4498 |
| Pomalidomide | Pomalidomide 4 mg/1 | CapsuleOral | Apotex Corp. | 60505-4500 |